$ACON

Wesemann William purchased $5K of ACON

Wesemann William purchased 2,150 shares of Aclarion, Inc. (ACON) at $2.34 on 2026-08-13.

Original reporting
SEC EDGAR · Wesemann William
Published Aug 17, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 1:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ACON
Bullish
medium confidence
Mentioned
$ACON
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACONBullishLow
01

Why it matters

The newest information is the disclosed open-market purchase details and post-transaction holdings; it does not include earnings, guidance, contracts, or regulatory actions.

02

Market read

Traders may note a small director buy, but the transaction size and lack of fundamental updates suggest limited trading impact.

03

What to watch

The filing states no 10b5-1 plan, but it still does not explain intent, timing rationale, or whether the director already held a large position.

Relevance 4/10Novelty 3/10Timing: Form 4 filed 2026-08-17, covering a 2026-08-13 purchase.

Background

This is an SEC Form 4 insider transaction for Aclarion, Inc. (ACON) by director Wesemann William.

Company-level read

Ticker impact

$ACONBullishMedium confidence
Context

Aclarion director Wesemann William filed a Form 4 for an open-market purchase of 2,150 shares at $2.34 on 2026-08-13.

Expected impact

Likely limited near-term price impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

Form 4 insider buys can be read as confidence, but this transaction is modest ($5,031) and provides no new company-specific financial or strategic information.

Market effects

No clear sector read-through from a single small insider buy.

None.

None.

Counterpoint

Insider buys can be routine (tax, diversification, or pre-planned behavior) and may not reflect a near-term change in outlook.

Key entities

  • Aclarion, Inc.

    Subject of the Form 4 insider transaction (ACON).

  • Wesemann William

    Director who purchased 2,150 shares at $2.34 on 2026-08-13.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACONMed

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI

Aclarion (Nasdaq: ACON) said it launched a U.S. Market Access Program with PRIA Healthcare to advance reimbursement and commercial adoption of its AI platform Nociscan for chronic low back pain. PRIA will support payer engagement, prior authorization and appeals. Aclarion cited UK payer approvals from three of four major private insurers as a basis for U.S. coverage discussions.

$ACONMedAI 8/10

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Aclarion (Nasdaq: ACON) said it has agreed with the Institute of Neuro Innovation in Los Angeles to expand availability of its Nociscan platform. The INI team led by neurosurgeon Amir Vokshoor will generate real-world evidence comparing Nociscan’s lumbar disc chemical biomarker data with bone metabolic information from SPECT-CT to support treatment decisions for chronic low back pain.